Promontory Therapeutics Expands Phase 2 Trial of PT-112 in Metastatic Castrate-Resistant Prostate Cancer to France

Promontory Therapeutics Inc., a clinical stage pharmaceutical company specializing in innovative treatments for cancer, has recently expanded its Phase 2 trial of PT-112 to include patients in France. This exciting development marks the company's first foray into the French market and brings hope to individuals with metastatic castrate-resistant prostate cancer (mCRPC). The trial, which is curre..